Cerebrospinal fluid biomarkers of central dopamine deficiency predict Parkinson's disease
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 50, 108-112
Abstract
No abstract availableKeywords
Funding Information
- Division of Intramural Research
- NINDS
- NIH (ZIA NS003034)
This publication has 10 references indexed in Scilit:
- Cardiac sympathetic denervation predicts PD in at-risk individualsParkinsonism & Related Disorders, 2018
- Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect ofl‐DOPAtreatment and changes in levodopa‐induced dyskinesiaJournal of Neurochemistry, 2017
- Parkinson risk in idiopathic REM sleep behavior disorderNeurology, 2015
- Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson’s disease and other synucleinopathiesBrain, 2012
- Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progressionAnnals of Neurology, 2010
- Simple Ratio Analysis of 18F-Fluorodopa Uptake in Striatal Subregions Separates Patients with Early Parkinson Disease from Healthy ControlsJournal of Nuclear Medicine, 2009
- Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophyParkinsonism & Related Disorders, 2008
- Orthostatic hypotension as an early finding in Parkinson’s diseaseClinical Autonomic Research, 2006
- Idiopathic hyposmia as a preclinical sign of Parkinson's diseaseAnnals of Neurology, 2004
- Rate of progression in Parkinson's disease: A 6‐[18F]fluoro‐L‐dopa PET studyMovement Disorders, 2001